A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Study of Drug for the Treatment of Cytomegalovirus (CMV) Infection in Stem Cell Transplant Recipients
Sponsor: Shire ViroPharma, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAR2859
U.S. Govt. ID: NCT02927067
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see which study drug is the better treatment for CMV infection. The study also wants to see how safe the study drugs are. The study drugs are Maribavir and Valganciclovir. Those who participate in the study will not know which drug they are taking. The study team will not know either.
This study is closed
Investigator
Ran Reshef, MD
Do You Qualify?
Are you 18 years or older? Yes No
Do you have Cytomegalovirus (CMV) infection? Yes No
Are you a recepient of a hematopoietic stem cell transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE